Table 1.

Strain 44/76-SL hSBA Results: Proportion of Individuals With hSBA ≥4 and Geometric Mean Titers, by Visit and Group

hSBA Titer ≥4
AgeGroupNo.No. (%)95% CISBA GMT (95% CI)
5 moTest7371 (97.3)90.5–99.748.6 (37.2–63.4)
6 moControl7421 (28.4)18.5–40.12.1 (1.7–2.4)
12 moTest4814 (29.2)17.0–44.12.2 (1.8–2.8)
13 moTest7674 (97.4)90.8–99.772.1 (51.7–100.4)
Control7747 (61.0)49.2–72.04.7 (3.7–6.1)
hSBA Titer ≥4
AgeGroupNo.No. (%)95% CISBA GMT (95% CI)
5 moTest7371 (97.3)90.5–99.748.6 (37.2–63.4)
6 moControl7421 (28.4)18.5–40.12.1 (1.7–2.4)
12 moTest4814 (29.2)17.0–44.12.2 (1.8–2.8)
13 moTest7674 (97.4)90.8–99.772.1 (51.7–100.4)
Control7747 (61.0)49.2–72.04.7 (3.7–6.1)

Abbreviations: CI, confidence interval; hSBA, human complement serum bactericidal antibody; SBA, serum bactericidal antibody.

Table 1.

Strain 44/76-SL hSBA Results: Proportion of Individuals With hSBA ≥4 and Geometric Mean Titers, by Visit and Group

hSBA Titer ≥4
AgeGroupNo.No. (%)95% CISBA GMT (95% CI)
5 moTest7371 (97.3)90.5–99.748.6 (37.2–63.4)
6 moControl7421 (28.4)18.5–40.12.1 (1.7–2.4)
12 moTest4814 (29.2)17.0–44.12.2 (1.8–2.8)
13 moTest7674 (97.4)90.8–99.772.1 (51.7–100.4)
Control7747 (61.0)49.2–72.04.7 (3.7–6.1)
hSBA Titer ≥4
AgeGroupNo.No. (%)95% CISBA GMT (95% CI)
5 moTest7371 (97.3)90.5–99.748.6 (37.2–63.4)
6 moControl7421 (28.4)18.5–40.12.1 (1.7–2.4)
12 moTest4814 (29.2)17.0–44.12.2 (1.8–2.8)
13 moTest7674 (97.4)90.8–99.772.1 (51.7–100.4)
Control7747 (61.0)49.2–72.04.7 (3.7–6.1)

Abbreviations: CI, confidence interval; hSBA, human complement serum bactericidal antibody; SBA, serum bactericidal antibody.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close